At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
AMD3100 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Autologous Peripheral Blood Stem Cells Collected From Patients With Lymphoma
In Brief
A Phase 2 clinical trial evaluating AMD3100, G-CSF, and 1 other intervention for Lymphoma, Non-Hodgkin and Hodgkin Disease. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of intravenous AMD3100 added to a standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for lymphoma. The investigators hypothesize that after stem cell mobilization with G-CSF plus IV AMD3100, a significantly higher proportion of lymphoma patients will collect ≥ 2 x 10E6 CD34+ cells/kg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin, Hodgkin Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartNov 2008
Primary CompletionSep 2012
Study CompletionSep 2013
TodayJul 2026
First PostedAug 13, 2008
Enrollment StartNov 1, 2008
Primary CompletionSep 1, 2012
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.9 years ago
Interventions
AMD3100drug
G-CSFdrug
Apheresisprocedure